CME in Minutes: Education in Oncology & Hematology
By Answers in CME
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Answers in CME
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 83
Description
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
| Episode | Date |
|---|---|
|
Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician
|
Apr 05, 2024 |
|
Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients
|
Apr 05, 2024 |
|
Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer
|
Apr 05, 2024 |
|
Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males
|
Mar 29, 2024 |
|
Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer
|
Mar 29, 2024 |
|
Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates
|
Mar 25, 2024 |
|
Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens
|
Mar 14, 2024 |
|
Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatment Landscape
|
Mar 08, 2024 |
|
Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors
|
Mar 06, 2024 |
|
Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy
|
Feb 26, 2024 |
|
Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?
|
Feb 26, 2024 |
|
Susana M. Campos, MD, MPH - Expanding the Potential of HER2-Directed Antibody-Drug Conjugates: Evidence and Application in New Tumor Types
|
Feb 22, 2024 |
|
John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies
|
Feb 14, 2024 |
|
Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens
|
Feb 14, 2024 |
|
Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes
|
Jan 10, 2024 |
|
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy
|
Jan 03, 2024 |
|
Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
|
Jan 03, 2024 |
|
Manish A. Shah, MD - Keeping Current on Frontline Immunotherapy-Chemotherapy Combinations: HER2-Positive and HER2-Negative Unresectable Advanced Gastric or GEJ Adenocarcinoma
|
Dec 29, 2023 |
|
Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
|
Dec 18, 2023 |
|
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy
|
Dec 18, 2023 |
|
Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach
|
Dec 18, 2023 |
|
Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer
|
Dec 18, 2023 |
|
Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm
|
Dec 05, 2023 |
|
Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors
|
Nov 13, 2023 |
|
Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates
|
Oct 31, 2023 |
|
Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC
|
Oct 11, 2023 |
|
Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches
|
Sep 25, 2023 |
|
Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer
|
Sep 22, 2023 |
|
Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?
|
Sep 19, 2023 |
|
Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies
|
Sep 19, 2023 |
|
Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC
|
Sep 05, 2023 |
|
Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2
|
Sep 05, 2023 |
|
Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies
|
Aug 23, 2023 |
|
Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC
|
Aug 17, 2023 |
|
Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better Pathways of Care
|
Jul 27, 2023 |
|
Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
|
Jul 27, 2023 |
|
Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations
|
Jul 07, 2023 |
|
Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care
|
Jul 03, 2023 |
|
Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
|
Jul 03, 2023 |
|
Tanios Bekaii-Saab, MD / Kelley A. Rone, DNP, AGNP-c - Providing Holistic Care for Hand-Foot Skin Reaction to Improve Outcomes for Patients on Multikinase Inhibitor Therapy for CRC
|
Jun 27, 2023 |
|
Axel Hauschild, MD - Advancing Outcomes in Surgically Resectable Cutaneous Squamous Cell Carcinoma: Carving New Paths Forward With Immunotherapies
|
Jun 15, 2023 |
|
Sara A. Hurvitz, MD, FACP / Miguel Martín, MD, PhD - Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens
|
Jun 15, 2023 |
|
Javier Cortés, MD / Sarah Donahue, MPH, ANP, AOCNP - Putting Patients First: Optimizing Outcomes via Collaborative Care in Pretreated Advanced Triple Negative Breast Cancer Treatment
|
Jun 12, 2023 |
|
Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations
|
Jun 08, 2023 |
|
Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?
|
May 31, 2023 |
|
Jonathan Schoenfeld, MD, MPH - Evolving the Treatment Landscape in Head and Neck Squamous Cell Carcinoma: Promoting Apoptosis With Emerging Antagonists of Inhibitors of Apoptosis Proteins
|
May 31, 2023 |
|
Suriya Jeyapalan, MD, MPH - Expert Conversations in Newly Diagnosed Glioblastoma: Discussing TTFields as a Recommended Adjuvant Therapeutic Option
|
May 23, 2023 |
|
John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm
|
May 04, 2023 |
|
Hussein Tawbi, MD, PhD / Laura K. Ferris, MD, PhD - Optimizing Outcomes in Advanced Melanoma Through Enhanced Collaboration: A Real-World Multidisciplinary Approach
|
May 04, 2023 |
|
Sergio Giralt, MD, FACP, FASTCT - Charting a New Course in the Treatment Paradigm of Relapsed/Refractory Multiple Myeloma: The Current Snapshot of Novel CAR T-Cell Therapies
|
Apr 21, 2023 |
|
Christine E. Jones, BMBS, PhD - A Full-Throated Appeal to Personalize Care in Advanced Gastroesophageal Junction (GEJ) and Esophageal Cancers: Where Do Immunotherapy-Based Regimens Fit In?
|
Apr 10, 2023 |
|
Reinhard Dummer, Prof. Dr. med - Making the Case for a Systemic Approach to Advanced Basal Cell Carcinoma: A Multidisciplinary Team Strategy to Optimize Long-Term Care
|
Mar 30, 2023 |
|
Giovanni L. Ceresoli - Advancing Care in Advanced Non–Small-Cell Lung Cancer With Combination Locoregional and Systemic Therapies
|
Mar 30, 2023 |
|
Nicolas Girard, MD, PhD - Fortifying Outcomes in Unresectable Stage III Non–Small-Cell Lung Cancer: Current and Evolving Strategies to Optimize the Use of Consolidation Immunotherapy
|
Feb 15, 2023 |
|
Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes
|
Feb 15, 2023 |
|
Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors
|
Feb 15, 2023 |
|
Enriqueta Felip, MD, PhD - Breaking News for Frontline Dual Immunotherapy and Chemotherapy Combination Regimens: Improving Patient Outcomes in Advanced NSCLC
|
Jan 09, 2023 |
|
Omid Hamid, MD - An Expert Conversation About Anti-LAG-3/PD-1 Combinations: Exploring the Clinical Impact of Approved and Emerging Combinations in the Advanced Melanoma Treatment Landscape
|
Dec 20, 2022 |
|
Todd Schlesinger, MD, FAAD - Optimizing Immunotherapy in Patients With Advanced Basal Cell Carcinoma: Practical Strategies to Inform Care
|
Dec 13, 2022 |
|
Suriya Jeyapalan, MD, MPH - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: A Focus on Novel Adjuvant Therapies
|
Dec 13, 2022 |
|
Charles B. Simone, II, MD, FACRO - Thinking Outside the Box to Advance Cancer Care: The Latest Evidence and Guidance on Novel Portable Electric Field Therapies
|
Nov 17, 2022 |
|
Aditya Bardia, MD, MPH - Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?
|
Nov 15, 2022 |
|
Arndt Vogel, MD, PhD - Emerging Trends for Treating Advanced Biliary Tract Cancer: Where Does the Evidence Stand on Immunochemotherapy Combinations
|
Nov 07, 2022 |
|
Eric Jonasch, MD - The Clinical Implications of Current Treatment Options for von Hippel-Lindau Disease
|
Nov 07, 2022 |
|
Samuel L. Washington III, MD, MAS - Bridging the Gap in Prostate Cancer Outcomes for Black Men: Elevating Approaches to Androgen Deprivation Therapy
|
Nov 07, 2022 |
|
Peter R. Galle, MD, PhD - Moving Forward with the Management of Unresectable Hepatocellular Carcinoma: Evaluating the Impact of Emerging First-line Dual Immunotherapy Combination Regimens
|
Oct 28, 2022 |
|
Ghassan Abou-Alfa, MD, MBA - Leveraging Combinatorial Approaches in Hepatocellular Carcinoma: An Exploration of the Clinical Implications of the Available Data
|
Oct 28, 2022 |
|
Javier Cortés, MD, PhD - BRCA Testing in Patients With Early-Stage Breast Cancer: A Focus on the Patient Conversation
|
Oct 24, 2022 |
|
Aiwu Ruth He, MD, PhD - Reshaping the Landscape of Advanced Biliary Tract Cancer: The Evidence for Combination Immunochemotherapy
|
Oct 20, 2022 |
|
Joshua Richter, MD - Charting a New Course in Relapsed/Refractory Multiple Myeloma: The Emergence of BCMA-Targeted Therapies
|
Oct 14, 2022 |
|
Hope S. Rugo, MD, FASCO - Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes with Emerging Antibody Drug Conjugates
|
Oct 04, 2022 |
|
Tanios Bekaii-Saab, MD / Beth McLellan, MD - Managing Hand-Foot Skin Reaction: Interdisciplinary Strategies for Patients on Multikinase Inhibitors
|
Oct 04, 2022 |
|
David Paul Carbone, MD, PhD - Big Advances in Resectable Non–Small-Cell Lung Cancer With Neoadjuvant Immunotherapy
|
Oct 03, 2022 |
|
Sagar Lonial, MD - Rebooting the Treatment of Relapsed/Refractory Multiple Myeloma: A New Look at Novel Cereblon-Targeted Agents
|
Sep 30, 2022 |
|
Shalina Gupta-Burt, MD - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: Personalizing Treatment and Managing Adverse Events
|
Sep 06, 2022 |
|
Orlando M. Gutierrez, MD - Reducing Disparities in Anemia of CKD Management
|
Sep 05, 2022 |
|
George Kassianos, CBE, MD (Hons), FRCGP - A Vaccinator’s Guide to Viral Vector–Based COVID-19 Vaccines
|
Sep 02, 2022 |
|
Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?
|
Aug 31, 2022 |
|
Antonio González Martin, MD, PhD - Exploring the Evolving Role of PD-1/PD-L1 Inhibitors in Cervical Cancer: Setting Sights on Locally Advanced Disease
|
Aug 31, 2022 |
|
Solange Peters, MD, PhD - Harnessing Frontline Dual Immunotherapy and Chemotherapy Combination Regimens for Advanced NSCLC: Strategies to Enhance Individualized Care
|
Aug 23, 2022 |
|
Mary O'Brien, MD, FRCP - Moving Immune Checkpoint Inhibitors to Resected Early-Stage Non-Small Cell Lung Cancer: Emerging Strategies for Adjuvant Therapy
|
Aug 12, 2022 |
|
Barbara Burtness, MD - Rethinking Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Promoting Apoptosis with Emerging Therapies
|
Aug 09, 2022 |
|
Alexander Drilon, MD - Hitting the Mark in Personalizing Oncology Care: A Clinician’s Guide to Best Practices in Biomarker Testing
|
Aug 02, 2022 |